NEW YORK (GenomeWeb) – BG Medicine today reported a 41 percent decline year over year in its first quarter revenues. 

For the three months ended March 31, the Waltham, Massachusetts-based firm said that revenues totaled $437,000, down from $739,000 in Q1 2014. BG Medicine said that the drop resulted from a decline in orders from its largest clinical laboratory customer. 

Net loss for the recently completed quarter narrowed to $1.3 million, or $.04 per share, compared to a net loss of $2.2 million, or $.08 per share, in Q1 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.